Peptide library / ARA-290

ARA-290

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the tissue-protective region of erythropoietin.

Peptide & blend guide

The short version

Why people discuss it
Discussed for neuropathic pain and small-fiber-neuropathy-related symptoms. Community interest does not establish benefit or a suitable treatment.
What it is
ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the tissue-protective region of erythropoietin.
Biggest caution
Small human or disease-specific studies do not establish a general recovery or neuropathy protocol. Cibinetide is distinct from erythropoietin and from unverified products sold as ARA-290.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

Subcutaneous injection

Study reference · Population-specific
Amount
4 mg
Frequency
Once daily
Duration / phase
28 days

Selected investigational human-study reference: 4 mg subcutaneously daily for 28 days. A different publisher page adds a lower start and extends to 8–16 weeks; that is not the same trial regimen. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library